Idorsia Pharmaceuticals Ltd (IDRSF) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, good morning to you all. This is Andrew Weiss, and I want to welcome everyone to our webcast conference call to finally discuss the full year 2023 and first quarter 24 results with you. As you may have noticed today, we've also filled your email box with other important releases regarding governance structure at IDORSEO. I will shortly hand over to our CEO, Jean-Paul Closel, and our CFO, André Muller, to give you additional color on everything we've announced today. Then, joining us for the Q&A session, we have our general manager and president of the U.S. organization, Tosh Butt, and our soon-to-be president of Eidosia UCAN region, Benjamin Limahl, who will be taking over from Jean-Yves Chatelain. Next slide, please. Before handing over the microphone, I need to remind everyone that we will be making forward-looking statements today. You have therefore been appropriately warned about the risks and opportunities of investing in IDORSA shares. With that, Jean-Paul, the floor is yours. Next slide. Thank you, Andrew. And after 24 years, this is going to be my last webcast as a CEO. And I think it's a good time to really think of what we have achieved since the creation seven years ago of iDorcia. We did quite a lot since we brought three drugs to the market, PIVLAS, QVVIC, and TRIVIO. And also, we, during this time, we built a global marketing organization in the U.S., in the main country, in Europe, and also in Japan. And, of course, we launched QBVIC in the U.S. and in the main European countries. We created, in addition to these three products which went on the market, a late-stage pipeline, and we continued to discover new drugs and built a very strong pipeline. We also reacquired the rights of aposetantin from Johnson & Johnson. And of course, all t...